A profitable Swiss biopharma with a capital-efficient model, strong global partnerships, and a focus on anti-infectives, is driving growth through its leading brands Cresemba and Zevtera, a robust late-stage pipeline, and significant non-dilutive funding. FY 2025 saw strong revenue and profit, with guidance for further growth and new product launches expected to double sales.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.